Yongkun Sun

Summary

Country: China

Publications

  1. Sun Y, Du F, Gao M, Ji Q, Li Z, Zhang Y, et al. Anlotinib for the Treatment of Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer. Thyroid. 2018;: pubmed publisher
    ..Anlotinib demonstrated a durable antitumor activity with manageable adverse event profile in locally advanced or metastatic MTC. ..
  2. Zhan X, Zhang S, Cao B, Wang J, Li J, Sun Y, et al. Clinicopathological characteristics and treatment outcomes of Chinese patients with genitourinary embryonal rhabdomyosarcoma. World J Surg Oncol. 2015;13:190 pubmed publisher
    ..Our findings suggest that metastasis predicts a poor prognosis. Chemotherapy played an important role in comprehensive treatment. Palliative and neo-adjuvant chemotherapy could increase median survival time. ..
  3. Zhu Y, Sun Y, Hu S, Jiang Y, Yue J, Xue X, et al. Comparison of five tumor regression grading systems for gastric adenocarcinoma after neoadjuvant chemotherapy: a retrospective study of 192 cases from National Cancer Center in China. BMC Gastroenterol. 2017;17:41 pubmed publisher
    ..We recommend Mandard-TRG system for GC after neoadjuvant chemotherapy due to its better prediction of prognosis. ..